Johnson & Johnson (JNJ) is Ronna Sue Cohen’s 2nd Largest Position

Ronna Sue Cohen reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,843 shares of the company’s stock after selling 667 shares during the period. Johnson & Johnson makes up about 3.5% of Ronna Sue Cohen’s investment portfolio, making the stock its 2nd biggest holding. Ronna Sue Cohen’s holdings in Johnson & Johnson were worth $4,530,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Schaper Benz & Wise Investment Counsel Inc. WI lifted its position in shares of Johnson & Johnson by 0.5% during the first quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 114,681 shares of the company’s stock worth $14,283,000 after purchasing an additional 544 shares during the last quarter. Cedar Wealth Management LLC lifted its position in shares of Johnson & Johnson by 5.3% during the first quarter. Cedar Wealth Management LLC now owns 3,294 shares of the company’s stock worth $410,000 after purchasing an additional 167 shares during the last quarter. Usca Ria LLC lifted its position in shares of Johnson & Johnson by 4.7% during the first quarter. Usca Ria LLC now owns 49,607 shares of the company’s stock worth $6,179,000 after purchasing an additional 2,244 shares during the last quarter. Willingdon Wealth Management lifted its position in shares of Johnson & Johnson by 11.8% during the first quarter. Willingdon Wealth Management now owns 12,958 shares of the company’s stock worth $1,614,000 after purchasing an additional 1,372 shares during the last quarter. Finally, WASHINGTON TRUST Co lifted its position in shares of Johnson & Johnson by 2.3% during the first quarter. WASHINGTON TRUST Co now owns 108,714 shares of the company’s stock worth $13,540,000 after purchasing an additional 2,402 shares during the last quarter. Hedge funds and other institutional investors own 65.70% of the company’s stock.

Several brokerages have recently commented on JNJ. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research report on Monday, September 18th. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research report on Wednesday, October 18th. Citigroup increased their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Jefferies Group raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the stock from $145.00 to $157.00 in a research report on Wednesday, October 11th. Finally, Argus raised their target price on shares of Johnson & Johnson from $145.00 to $165.00 and gave the stock a “positive” rating in a report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $145.47.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $140.12 on Friday. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $144.35. The company has a market cap of $376,440.00, a P/E ratio of 24.33, a price-to-earnings-growth ratio of 2.87 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter last year, the business earned $1.68 earnings per share. Johnson & Johnson’s revenue was up 10.3% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a $0.84 dividend. The ex-dividend date of this dividend was Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s payout ratio is currently 58.33%.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/24/johnson-johnson-jnj-is-ronna-sue-cohens-2nd-largest-position.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit